Scynexis Inc

NASDAQ:SCYX   3:59:14 PM EDT
7.58
-0.43 (-5.37%)
Products

Scynexis Announces FDA Approval Of Brexafemme (Ibrexafungerp Tablets) As The First And Only Oral Non-Azole Treatment For Vaginal Yeast Infections

Published: 06/02/2021 11:38 GMT
Scynexis Inc (SCYX) - Scynexis Announces FDA Approval of Brexafemme® (ibrexafungerp Tablets) As the First and Only Oral Non-azole Treatment for Vaginal Yeast Infections.
Scynexis Inc - U.S. Commercial Launch Expected in Second Half of 2021 in Partnership With Amplity Health.